drugs. Within the cytosol are many mitochondria, membrane-bound organelles that are the major source of energy production for the cell. Mitochondria contain their own genome, which encodes some of their proteins needed for the production of energy. This DNA is translated into protein by the mitochondria's own ribosomes. Since mitochondria are believed to be derived from a prokaryotic ancestor (Alberts et al., 1989) , their ribosomes more closely resemble those of prokaryotes than those of the eukaryotic cytosol, making them a possible target for aminoglycosides.
A rare genetic trait which confers hypersensitivity to aminoglycoside antibiotics, and is inherited maternally, exists in the human population. A rare trait exists, in which humans exposed to therapeutic levels of aminoglycosides develop significant hearing loss. By investigating 41 human pedigrees that exhibited this aminoglycoside hypersensitivity trait (Higashi, 1989; Hu et al., 1990) , it was shown that transmission of the trait is through the maternal lineage (see Figure 1 ). Maternal inheritance is the hallmark of mitochondrially inherited disorders (see Wallace, 1987) . Mitochondria of the fetus are inherited almost exclusively from the mother. Many genetic diseases of the mitochondrion have recently been described (reviewed in Wallace, 1992 Wallace, , 1993 , and one of the most common phenotypes of these diseases is sensorineural deafness, suggesting that cells in the cochlea may have a more critical requirement for mitochondrial function (see, for example, Elverland & Torbergsen, 1991; Lombes, Bonilla, & DiMauro, 1989) .
A mitochondrial mutation occurs in 100% of pedigrees with a trait for hypersensitivity to aminoglycosides. Genetic variation in the mitochondrial 12S and 16S ribosomal RNA (rRNA) subunits was surveyed in three Chinese pedigrees (Prezant et al., 1993) , and in two Japanese pedigrees (Hutchin et al., 1993) . Five of these five pedigrees shared a rare transition mutation of A to G in the 12S rRNA gene at position 1555. This mutation is referred to as 1555 G . This same 1555 G mutation occurred in 0 of 274 Asians and 0 of 414 total controls (Table  1) , a statistically significant difference at the 99% confidence level from the observation of 1555 G in 5 of 5 deafness pedigrees surveyed (Hutchin et al., 1993) . The 1555 G mutation was also found at an elevated frequency (4/78) in sporadic cases of aminoglycoside-induced deafness in which a family history of deafness was not available (Hutchin et al., 1993) , an occurrence which is also significantly different from that in the control population.
The 1555 position occurs in a region homologous to that which is known to be involved in aminoglycoside binding to the bacterial rRNA (Cundliffe, 1987; Hornig, Woolley, & Luhrmann, 1987; Moazed & Noller, 1987) . This lends support to the notion that the hypersensitivity trait is the direct result of altered, and presumably increased, binding of aminoglycosides to the mitochondrial ribosome.
Clinical implications of the new molecular model of aminoglycoside hypersensitivity. Now that it is known that a particular mutation of the mitochondrial DNA, the 1555 G , is tightly associated with hypersensitivity to aminoglycoside antibiotics, it is conceivable that genetic screening of patients could occur before they receive aminoglycoside treatment. In that way, hypersensitive individuals could be identified before they are exposed to risk. Such genetic screening of humans is desirable on humanitarian grounds, but may not be feasible on economic grounds because of the rarity of the 1555 G mutation, which occurred with low frequency in controls (0/414).
Our recent data suggest, however, that persons of particular mitochondrial genetic backgrounds may be at much greater risk of having the 1555 G mutation than others. Because mitochondrial DNA (mtDNA) is inherited exclusively from mothers in humans, once deleterious variation arises within a particular mtDNA clone it remains linked to that clonal type. We have found that the 1555 G mutation is sevenfold more frequent, on average, in one mtDNA type than another (Hutchin & Cortopassi, 1995) . This group of mtDNAs is rare in the Caucasian population, but more frequent in the Asian population, which may explain the distribution of this form of deafness. Negative Darwinian selection is expected to rapidly eliminate mtDNAs bearing severely deleterious mutations; but mildly deleterious mutations whose phenotype is expressed after reproduction should persist on the mtDNA background in which they arose, and thus risk for mitochondrial genetic diseases may be quite different in different mtDNA groups.
The clinician should be aware of a possible mitochondrial genetic etiology in cases of suspected aminoglycoside-induced deafness. One warning sign would be the occurrence of such deafness to multiple individuals in a family after exposure to aminoglycosides. In such cases it would be prudent to test the individual's DNA for the 1555 G mutation. Knowing that the individual was positive for the 1555 G mutation would be beneficial in two respects. First, the patient could avoid reexposure to aminoglycosides and a possible worsening of the condition. Second, maternal relatives could be warned that they are at 100% risk for such aminoglycoside-induced deafness as well. Because we are quite interested in the distribution of this trait and this mutation in the human population, we would be happy to assay, at no charge, as many hair or blood samples for 
